Previous studies have demonstrated that RNAi-mediated silencing or small compound-mediated inhibition of USP7 resulted in destabilizing the MDM2/MDMX proteins that leading to activate the p53-mediated tumor suppression, thus USP7 can serve as a promising target for cancer treatment. Here, TP53 is linked to neoplasm.